The serum fructosamine assay, used to monitor shortterm clinical glycemic control, reportedly has several technical drawbacks. However, technical improvements have resulted in a new second-generation assay of fructosamine. We evaluated this second-generation assay (from Roche Diagnostics) in 529 nondiabetic and diabetic patients and found a highly significant correlation with results of the first-generation assay (r = 0.91, P <0.001).
over the previous two to three months; this measure has been used as the "gold standard" clinically for well over 10 years (3, 4). However, interest has been intense in evaluating other glycated serum proteins with shorter half-lives (i.e., albumin, with a half-life of 14-20 days), which reflect glycemic control over the previous two to four weeks (5-B) .
Determining glycated serum proteins by use of nitroblue tetrazolium (NBT) colorimetric methods-the serum fructosamine assay-was first described by Johnson et al. (9) in 1983. 1 Several clinical studies have shown the fructosamine assay to be a valid marker of short-term glycemic control (10) (11) (12) (13) . However, despite the clinical validity reported for the fructosamine assay, the NBT method has some drawbacks.
In particular, the nonspecific nature of the reaction allows interference by uric acid, bilirubin, and lipids (14, 15); other major concerns are the effects of albumin concentration on the measurement (16, 17) and assay calibration (18 To clinically validate this second-generation fructosainine assay, we compared the results of the firstgeneration assay with those of the second-generation assay for accurately monitoring an adult diabetic population during a 10-week intervention study. In addition, we performed a cross-sectional assessment of the utility of this assay in insulin-dependent, non-insulin-dependent, and nondiabetic subjects, to establish reference ranges for this assay and to evaluate correlations with glycated protein variables currently used in assessing glycemic control.
Patients and Methods
We recruited 529 patients (ages 18-70 years) for the cross-sectional aspect of study, of whom 230 were nondiabetics. The patients were from the outpatient clinics of the Department of Medicine and from the Diabetes 'Nonstandard abbreviations: NBT, nitroblue tetnazolium; CBG, capillary blood glucose; and FA-1, FA-2, first-and second-generation fructosamine assays, respectively. Research Clinics of the Bowman Gray School of Medicine. All patients gave informed consent, and the study was Figure 3 demonstrates the average weekly CBG of the 23 non-insulin-dependent diabetic patients in the intensive intervention phase of study. The CBG significantly increased during the two-week "off' medication period (P <0.05). Although the FA-2 result obtained during this period also increased by the end of week 2, the increase obtained was not significant (P = 0.08). After this two weeks, all patients responded to the clinical intervention by demonstrating a significant decrease in the average weekly CBG. At study initiation, the average weekly CBG value was 13.3 (SD 3) mmol/L, which decreased to 7.5 (SD 1.4) mmol/L by study completion (P Defined according to glycohemoglobinvalues: 4-7%, <10%, and alO% for nondlabetic,good/moderatecontrol, and poor control, respectively. b P <0.001 vs 'good/moderate' control. After clinical intervention was initiated, the results of each fructosamine assay were less at each week of study; by week 5 of intervention, values were in the high normal range established for each assay. In addition, by week 5 the average weekly CBG decreased into the normal range, as established for this study. The glycohemoglobin decreased during the study but was not in the normal range at the completion of the study (12.9% ± 3% vs 9.6% ± 2.6%, mean ± SD, P <0.001). FA-2 results correlated significantly with FA-1 results at each week of study (r = 0.87, P <0.001). In addition, FA-2 results correlated significantly with both the one-week average CBG (r = 0.64, P <0.001, Figure  5A ) and the three-week average (r = 0.61, P <0.001, with glycohemoglobin, being r = 0.77, P <0.001 at baseline, but only r = 0.34, P = 0.09 at week 8.
<0.001). FA-2 results also
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The above study confirms that the second-generation serum fructosamine assay is a valid short-term index of _________________________ glycemic control; its results correlated significantly with the outpatient mean glucose concentration in all 23 patients during the 10-week study period. In addition, the FA-2 results correlated well with the values measured by the FA-1 at each week of study. Therefore, this study demonstrates that both assays provide the same clinical information.
Our reference range for FA-2 (based on the 95th percentile) has an upper limit of normal of 289 mo1/L. This value agrees well with the upper limit of normal (285 unolJL) reported for 555 nondiabetic patients studied at four sites in Europe with the FA-2 (21) and is slightly greater than the value reported in a recent European fructosamine
.
The differences in upper limit for the reference range were probably attributable to the different groups studied (which included hospitalized nondiabetic patients), although the selection criteria for the reference groups were the same (21,22) . In determining the upper limit of normal in our study, we studied only ambulatory outpatients, and not hospitalized patients. Again using the 95th percentile, we report a value of 2.7 mmol/L for FA-1, which agrees with the value of 2.8 mmol/L noted in the package insert. It is not surprising to find that the serum fruc-
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tosamine correlates significantly with the glycohemoglobin, because we have previously reported significant correlations between serum fructosamine and glycohemoglobin (Hb A1, as determined by column chromatography) ranging from r = 0.7 to 0.82 in both insulindependent and non-insulin-dependent diabetics younger than 65 years and in elderly (older than 65) non-insulindependent diabetics (10,11,23). Our findings regarding correlation between the two assays agree well with values reported by other investigators (24) (25) (26) (27) . In con- flects average integrated glucose control over the previous two to three weeks, as demonstrated by this and other studies (10-12, 24) . Therefore, the correlation between these measures should be better in a diabetic population not subject to recent, intensive intervention, as demonstrated by the significant correlation detected initially in both our cross-sectionand intervention study patients. In a clinical setting not involving a recent intensive intervention, gradual changes in glycemic control should be reflected in parallel changes in both fructosaniine and glycohemoglobin (30) . However, once intensive intervention is undertaken, the serum fructosamine will show a rapid decrease over a short-term interval corresponding to a decrease in average glycemia, whereas there will be only a minimal decrease in the glycohemoglobin measured.
Thus the correlation between the two will decrease. After the patient has achieved stable, normal concentrations of blood glucose and fructosamine, the glycohemoglobin value will continue to decrease, reflecting the glycemic changes from weeks before. At that time, the correlation between the two assays would be expected to increase. Clearly, changes in serum fructosamine and glycohemoglobin values are not interchangeable; rather, both should be used in a pattern of intensive diabetic monitoring. The decrease in glycated proteins in serum as monitored with the fructosamine assay can predict a drop in glycohemoglobin over time. This indeed was the case in our studies, and suggests strongly that use of both assays is indicated clinically in the management of diabetic patients.
In summary, we have reported on the clinical validity of a second-generation fructosaniine assay that has improved technical performance over the first-generation assay. Results of the second-generation assay correlate clinically with those of the first-generation assay, correlate significantly with both one-and three-week outpatient average glucose concentrations, and provide an objective marker of short-term glycemic control. In addition, because both fructosamine assays accurately monitor short-term glycemic excursions, clinical correlation between glycohemoglobin and serum fructosamine should not always be expected; if used together, however, both analytes can provide valuable clinical information on antecedent glycemic control.
